James M Martinez
Overview
Explore the profile of James M Martinez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
695
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jensen R, Tassorelli C, Myers Oakes T, Bardos J, Zhou C, Dong Y, et al.
Front Neurol
. 2024 Jan;
14:1293163.
PMID: 38162453
Objective: Two phase 3 galcanezumab trials were conducted in Europe and North America to analyze the reduction of weekly cluster headache (CH) attack frequency in populations with episodic and chronic...
2.
Schwedt T, Myers Oakes T, Martinez J, Vargas B, Pandey H, Pearlman E, et al.
Neurol Ther
. 2023 Nov;
13(1):85-105.
PMID: 37948006
Introduction: There have been no prior trials directly comparing the efficacy of different calcitonin gene-related peptide (CGRP) antagonists for migraine prevention. Reported are the results from the first head-to-head study...
3.
Cotton S, Andrews J, Nichols R, Jackson J, Tockhorn-Heidenreich A, Milligan G, et al.
Curr Med Res Opin
. 2023 Aug;
39(12):1637-1647.
PMID: 37615206
Objective: To describe clinical characteristics and regional treatment patterns of episodic cluster headache (CH). Methods: A point-in-time survey of physicians and their patients with CH was conducted in the United...
4.
Riesenberg R, Gaul C, Stroud C, Dong Y, Bangs M, Wenzel R, et al.
Cephalalgia
. 2022 May;
42(11-12):1225-1235.
PMID: 35633025
Background: CGAR, a Phase 3b open-label study, evaluated the long-term safety of galcanezumab in patients with cluster headache who completed one of two Phase 3 double-blind studies in chronic or...
5.
Dodick D, Goadsby P, Ashina M, Tassorelli C, Hundemer H, Bardos J, et al.
Headache
. 2022 Apr;
62(4):453-472.
PMID: 35363381
Objective: To provide a review of challenges in clinical trials for the preventive treatment of cluster headache (CH) and highlight considerations for future studies. Background: Current guidelines for preventive treatment...
6.
Scott Andrews J, Kudrow D, Rettiganti M, Oakes T, Bardos J, Wenzel R, et al.
J Pain Res
. 2021 Jul;
14:2059-2070.
PMID: 34267550
Purpose: In a phase 3 study, galcanezumab significantly reduced the frequency of episodic cluster headache attacks across weeks 1-3 (primary endpoint) compared with placebo. However, multiple pain dimensions may contribute...
7.
Martinez J, Hindiyeh N, Anglin G, Kalidas K, Hodsdon M, Kielbasa W, et al.
Cephalalgia
. 2020 Apr;
40(9):978-989.
PMID: 32340471
Background: This analysis characterizes the immunogenicity profile of galcanezumab, a humanized monoclonal antibody that selectively binds calcitonin gene-related peptide and inhibits its activity, in phase 3 migraine trials. Methods: Immunogenicity...
8.
Dodick D, Goadsby P, Lucas C, Jensen R, Bardos J, Martinez J, et al.
Cephalalgia
. 2020 Feb;
40(9):935-948.
PMID: 32050782
Objective: To report efficacy and safety of galcanezumab in adults with chronic cluster headache. Background: Galcanezumab is a humanized monoclonal antibody that binds to calcitonin gene-related peptide and inhibits its...
9.
Goadsby P, Dodick D, Leone M, Bardos J, Oakes T, Millen B, et al.
N Engl J Med
. 2019 Jul;
381(2):132-141.
PMID: 31291515
Background: Episodic cluster headache is a disabling neurologic disorder that is characterized by daily headache attacks that occur over periods of weeks or months. Galcanezumab, a humanized monoclonal antibody to...
10.
Goadsby P, Dodick D, Martinez J, Ferguson M, Oakes T, Zhang Q, et al.
J Neurol Neurosurg Psychiatry
. 2019 Apr;
90(8):939-944.
PMID: 31004075
Background And Objective: As new migraine prevention treatments are developed, the onset of a preventive effect, how long it is maintained and whether patients initially non-responsive develop clinically meaningful responses...